NAPA, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced an agreement with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences in Poznan, Poland for the exclusive rights to a new and promising tumor treatment using an RNAi based therapeutic technology for the potential use against a broad range of cancers.
This technology, which specifically targets a novel cancer biomarker, was developed by the Institute in cooperation with Department of Neurosurgery and Neurotraumatology University of Medical Sciences in Poznan, Poland. Under the terms of the collaborative agreement, Senetek will have rights for all applications of the in-licensed technologies in exchange for undisclosed royalty payments to be paid to the Institute upon commercialization.
Frank Massino, CEO and Chairman of Senetek, commented, "We are extremely pleased that our relationship with the Institute of Bioorganic Chemistry of the Polish Academy of Sciences has resulted in another important addition to our technology portfolio. We look forward to the opportunities that lie ahead with this novel advancement in RNAi therapy."
About Senetek PLC
Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the
development of breakthrough technologies that target the science of healthy
aging. The Company's extensive research collaborations have resulted in a
strong pipeline of patented compounds and products with broad therapeutic
applications and a leading presence in dermatology. Senetek collaborates with
established specialty pharmaceutical companies in the final development and
marketing of its proprietary products, most recently resulting in the
development of the best-selling anti-aging product sold in the North American
physician market. For more in
|SOURCE Senetek PLC|
Copyright©2008 PR Newswire.
All rights reserved